Site Tx

Site Therapeutics (Site Tx) is a biotechnology company focused on decoding the genetic architecture of human immune cells to develop precision immune-modulating therapies. Spun out from the laboratory of Dr. Alex Marson at UCSF and the Gladstone Institutes, the company utilizes a high-throughput functional genomics platform to identify single-nucleotide determinants of immune cell function. By mapping the genetic "wiring" of T cells and other immune cells, Site Tx aims to create a new class of small molecule and cell-based medicines for autoimmune diseases, cancer, and infectious conditions. The company is backed by The Column Group and maintains strategic research collaborations, including a multi-year partnership with the Baylor College of Medicine to discover novel small molecule drug candidates.